Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5711245 | 1.00 | USP2 (0.64) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8694697 | 1.00 | USP2 (0.64) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5711344 | 0.93 | USP2 (0.61) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5711222 | 0.93 | USP2 (0.61) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5711223 | 0.92 | USP2 (0.60) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5711372 | 0.88 | USP2 (0.66) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6965437 | 0.87 | USP2 (0.64) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3184957 | 0.86 | USP2 (0.63) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5711299 | 0.86 | USP2 (0.63) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8842431 | 0.86 | USP2 (0.63) | USP2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| US-20100280120-A1 | COMPOUND INDUCING ANGIOGENESIS RESPONSE IN ISCHAEMIC TISSUES | Green Cross Therapeutics Private Limited (IN) | 2010-11-04 | — | — | US | disclosed |
| EP-1103560-B1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1103560-A1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-5710129-A | Inhibitors of SH2-mediated processes | ARIAD PHARMACEUTICALS, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1997031016-A2 | NEW INHIBITORS OF SH2-MEDIATED PROCESSES | ARIAD PHARMACEUTICALS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5658945-A | ANTICANCER AGENT; AIDS THERAPY; CONTROLLING INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5633280-A | ACCELERATED RECOVERY FROM CHEMOTHERAPY, RADIATION TREATMENT, BONE MARROW TRANSPLANTATION, INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| US-5616612-A | THERAPY FOR CANCER, AIDS, ANEMIA, INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-04-01 | — | — | US | disclosed |
| US-5602275-A | MAY BE USED TO ACCELERATE RECOVERY FROM NEUTROPENIA ACCOMPANYING RADIO- OR CHEMOTHERAPY, BONE MARROW TRANSPLANTATION OR INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-02-11 | — | — | US | disclosed |
| EP-0652228-B1 | Urethanes and ureas that induce cytokine production | AMERICAN CYANAMID CO (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5545662-A | USED TO ACCELERATE RECOVERY FROM NEUTROPENIA ACCOMPANYING RADIO OR CHEMOTHERAPY, BONE MARROW TRANSPLANTATION, OR INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0652228-A1 | Urethanes and ureas that induce cytokine production | AMERICAN CYANAMID COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | USP2 2527/4885PSEN1 3502/4885PSEN2 3673/4885 |
| US-20100280120-A1 | COMPOUND INDUCING ANGIOGENESIS RESPONSE IN ISCHAEMIC TISSUES | FLT4, TEK, VEGFA | USP2 4602/4885PSEN1 4783/4885PSEN2 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.